Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Conjugated linolenic acid (CLnA) refers to a group of positional and geometric isomers of octadecatrienoic acid (C18:3) characterized by the presence of three double bonds in a conjugated system. These isomers are mainly found in certain plant seed oils and differ from typical polyunsaturated fatty acids by having their double bonds separated by only one single bond. CLnA has been studied for its potential health benefits, including anticancer, antiobesity, antidiabetic, and anti-inflammatory effects. The biological activity and physiological functions of CLnA depend on the specific isomer present; different isomers may have distinct metabolic pathways and health impacts. Mechanistically, some effects are thought to be mediated through modulation of lipid metabolism, inflammation pathways, or cellular signaling processes related to disease prevention or management[6]. Research into the clinical applications and mechanisms of action for individual CLnA isomers remains ongoing.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on conjugated linolenic acid.